Results 131 to 140 of about 1,634 (161)

Race-Based Guidance and Nirsevimab

JAMA Pediatrics
This Viewpoint discusses the current Advisory Committee on Immunization Practices and American Academy of Pediatrics race-based guidelines on the administration of nirsevimab and suggested race-conscious revision of the current guidance.
Joshua T B, Williams, Florence, Wu
openaire   +2 more sources

Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children

Pediatrics
BACKGROUND AND OBJECTIVES Immunocompromised children may have increased risk for severe respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI), potentially leading to prolonged hospitalization, intensive care, and death.
Joseph, Domachowske, Ulrika Wählby, Hamrén, Irfana, Banu, Roberta, Baronio, Bhanu, Basavaraju, Anthonet, Koen, Amanda, Leach, Vaishali S, Mankad, Pia S, Pannaraj, Pere, Soler-Palacin, Therese, Takas, Masaaki, Mori, Tonya, Villafana   +12 more
openaire   +2 more sources

Balanced on the Biggest Wave: Nirsevimab for Newborns

Neonatal Network
Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete
Christopher, McPherson, Christine R, Lockowitz, Jason G, Newland   +2 more
openaire   +2 more sources

Nirsevimab Administration During the Birth Hospitalization

Hospital Pediatrics
BACKGROUND Respiratory syncytial virus (RSV) is the leading cause of newborn hospitalization. In July 2023, nirsevimab, a monoclonal antibody to protect infants against RSV and reduce severe illness, was approved. Nirsevimab is the newest birth hospitalization immunization.
Shayda, Daneshvari, Philip, Lee, Sheri L, Nemerofsky   +2 more
openaire   +2 more sources

Nirsevimab-alip

Clinical Therapeutics, 2023
openaire   +4 more sources

RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing

Pediatrics
BACKGROUND Data describing respiratory syncytial virus (RSV) neutralizing antibody (nAb) levels for nirsevimab, a recently approved, extended half-life, anti-RSV fusion protein (F protein) monoclonal antibody, relative to the previous standard of care, palivizumab ...
Deidre, Wilkins, Ulrika, Wählby Hamrén, Yue, Chang, Lindsay E, Clegg, Joseph, Domachowske, Janet A, Englund, William J, Muller, Amanda, Leach, Elizabeth J, Kelly, Tonya, Villafana   +9 more
openaire   +2 more sources

Nirsevimab and Acute Bronchiolitis Episodes in Pediatric Emergency Departments

Pediatrics
BACKGROUND AND OBJECTIVES In the 2023–2024 respiratory syncytial virus (RSV) season, Spain became one of the first countries to introduce universal RSV prophylaxis, during which all infants born at this time were eligible to receive nirsevimab. Locally, most Spanish
Andina Martinez, David, Claret Teruel, Gemma, Gijon Mediavilla, Manuel, Camara Otegui, Amaia, Banos Lopez, Laura, de Miguel Lavisier, Begona, Ferrero Garcia-Loygorri, Clara, Sanchez Tatay, Victoria, Pavlovic Nesic, Svetlana, Clerigue Arrieta, Nuria, Gimeno-Hernandez Garza, Veronica, Guerra Diez, Jose Lorenzo, Ranera Malaga, Adrian, Escalada Pellitero, Silvia, Barrueco Ramos, Clara, Alonso-Cadenas, Jose Antonio   +15 more
openaire   +3 more sources

Safety of timely immunization with nirsevimab in hospitalized preterm infants

Vaccine
We aimed to assess the safety profile of nirsevimab in hospitalized preterm infants (PT). We conducted an observational, uncontrolled, prospective study in clinically stable PT admitted to the neonatal unit. One hundred and ten PT were eligible for immunization; uptake was 93.5 % (n = 103) (median GA and BW of 33 weeks and 1892 g, respectively), and a ...
Giannina, Izquierdo, Rodolfo, Villena, Camila, Cabrera, Javiera, Albornoz, Natalie, Hueichao, Carolina, Guerra, Juan Pablo, Torres   +6 more
openaire   +2 more sources

Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in Infants

NEJM Evidence
In pivotal trials, nirsevimab showed promising efficacy in reducing hospitalizations for respiratory syncytial virus-associated lower respiratory tract infections (RSV-LRTIs). Nirsevimab's real-world effectiveness needs to be assessed.This population-based study used the French National Health Data System.
Marie Joelle, Jabagi, Jérémie, Cohen, Marion, Bertrand, Martin, Chalumeau, Mahmoud, Zureik   +4 more
openaire   +2 more sources

New drug: nirsevimab

Ge-Bu, 2023
openaire   +1 more source